Development of a novel live attenuated African Swine Fever vaccine based in the deletion of gene I177L
AssigneeThe United States of America as represented by the Secretary of Agriculture
InventorsDouglas P. Gladue, Manuel V. Borca
Life of this patent
Estimating the term…
Abstract
Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate (“ASFV-G”). An exemplary vaccine comprises the ASFV-GΔI1771 modified virus, a recombinant ASFV-G modified by deleting a portion of the I177L ORF rendering the I177L gene nonfunctional.
Claims7
A genetically modified virus, wherein the virus genome comprises a viral genome at least 95% identical to SEQ ID NO:
- 2.
A recombinant ASFV mutant virus, comprising a synthetic mutation in the I177L open reading frame or in a regulatory element controlling the expression of the I177L protein, resulting in a non-functional genomic I177L gene, wherein the mutant ASFV comprises a genome at least 95% identical to SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.